BioCentury
ARTICLE | Clinical News

ATL1102: Phase I started

March 31, 2014 7:00 AM UTC

Antisense began an open-label, Australian Phase I trial to evaluate 400 mg subcutaneous ATL1102 on days 1, 3 and 5 with or without G-CSF for 5 days in 10 healthy volunteers. Antisense has rights to AT...